CD5-mediated specific delivery of DNA to T lymphocytes: compartmentalization augmented by adenovirus

Merwin, June R.; Carmichael, Ellen P.; Noell, G; DeRome, Mary; Thomas, Wendy; Robert, Norma; Spitalny, George L.; Chiou, Henry C.

doi:10.1016/0022-1759(95)00150-9

Cited by 21 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, FOL‐PEG‐PLL/PEI/DNA complexes were transported within A549 cells by a non‐specific adsorptive endocytosis process. This is consistent with many previous results of FOL receptor mediated targeting of anti‐cancer agents using various carriers such as liposomes, micelles, and nano‐particles 33–40. With increasing FOL‐PEG‐PLL/DNA ratio, the gene expression extent steadily increased and it showed the highest transfection efficiency of 6.97 × 10 8 RLU/mg protein at a weight ratio of 1.5.…”

Section: Resultssupporting

confidence: 92%

Folate Receptor‐Mediated Gene Delivery Using Folate‐Poly(ethylene glycol)‐Poly(L‐lysine) Conjugate

Cho

Kim

Jeong

et al. 2005

Macromolecular Bioscience

View full text Add to dashboard Cite

For efficient receptor-mediated gene transfection, a new and simple formulation method based on using PEI and FOLPEGPLL conjugate was presented. Luciferase plasmid DNA and PEI were complexed to form slightly positive-charged nanoparticles, onto which FOL-PEG-PLL conjugate was surface coated. With increasing the coating amount of FOL-PEG-PLL conjugate, the FOL-PEG-PLL/PEI/DNA complexes exhibited increased surface zeta-potential values with concomitantly increased diameters, indicating that the PLL part was physically anchored on the surface of preformed PEI/DNA complexes with FOL moieties being exposed on the outside. The formulated complexes exhibited a considerably higher transfection efficiency against FOL receptor over-expressing KB cells than FOL receptor deficient A549 cells. This was caused by an enhanced cellular uptake of the resultant complexes via a receptor-mediated endocytosis process. The formulated complexes showed a higher gene expression level, even in the presence of serum, than the PEI/DNA or Lipofectamine/DNA complexes. This was attributed to the PEG chains present on the surface of complexes that could work as a protective shield layer against aggregation caused by non-specific protein adsorption. The FOL-PEG-PLL/PEI/DNA complexes also demonstrated better cell viability than the PEI/DNA complexes.(1)H NMR spectrum of FOL-PEG-PLL conjugate.

show abstract

Section: Resultssupporting

confidence: 92%

Folate Receptor‐Mediated Gene Delivery Using Folate‐Poly(ethylene glycol)‐Poly(L‐lysine) Conjugate

Cho

Kim

Jeong

et al. 2005

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…31 Antibodies generated against certain cell-specific receptors also have been used to direct gene transfer. Antibody-directed molecular conjugates have been targeted to: CD3, [32][33][34][35] CD5, 36 EGF-R, 37,38 and ErbB2. 39 Key to the efficacy of an antibody-directed molecular conjugate, however, is the ability of the antibody to trigger receptor internalization.…”

Section: Receptor Bindingmentioning

confidence: 99%

Intracellular trafficking of nonviral vectors

2005

View full text Add to dashboard Cite

“…Antibodies to the transferrin receptor [82], the anti-platelet endothelial cell adhesion molecule PECAM [86], the polymeric immunoglobulin receptor pIgR [83], anti-CD5 [87], and the ErbB-2 receptor [88] have been used for the targeting of liposomes [11, 89], polylysine polyplexes [90], PEI polyplexes [86], and DNA-peptide complexes [91]. These systems in general mediated an increased uptake or expression in vivo compared to the untargeted vector.…”

Section: Extrinsic Targetingmentioning

confidence: 99%

Targeting of Synthetic Gene Delivery Systems

Schätzlein

2003

BioMed Research International

View full text Add to dashboard Cite

Safe, efficient, and specific delivery of therapeutic genes remains an important bottleneck for the development of gene therapy. Synthetic, nonviral systems have a unique pharmaceutical profile with potential advantages for certain applications. Targeting of the synthetic vector improves the specificity of gene medicines through a modulation of the carriers' biodistribution, thus creating a dose differential between healthy tissue and the target site. The biodistribution of current carrier systems is being influenced to a large extent by intrinsic physicochemical characteristics, such as charge and size. Consequently, such nonspecific interactions can interfere with specific targeting, for example, by ligands. Therefore, a carrier complex should ideally be inert, that is, free from intrinsic properties that would bias its distribution away from the target site. Strategies such as coating of DNA carrier complexes with hydrophilic polymers have been used to mask some of these intrinsic targeting effects and avoid nonspecific interactions. Preexisting endogenous ligand-receptor interactions have frequently been used for targeting to certain cell types or tumours. Recently exogenous ligands have been derived from microorganisms or, like antibodies or phage-derived peptides, developed de novo. In animal models, such synthetic vectors have targeted remote sites such as a tumour. Furthermore, the therapeutic proof of the concept has been demonstrated for fitting combinations of synthetic vectors and therapeutic gene.

show abstract

CD5-mediated specific delivery of DNA to T lymphocytes: compartmentalization augmented by adenovirus

Cited by 21 publications

References 33 publications

Folate Receptor‐Mediated Gene Delivery Using Folate‐Poly(ethylene glycol)‐Poly(L‐lysine) Conjugate

Folate Receptor‐Mediated Gene Delivery Using Folate‐Poly(ethylene glycol)‐Poly(L‐lysine) Conjugate

Intracellular trafficking of nonviral vectors

Targeting of Synthetic Gene Delivery Systems

Contact Info

Product

Resources

About